# Aileron Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aileron-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.aileronrx.com
- Total disclosed funding: $95M
- Latest round: Series E (Oct 29, 2014)
- Investors on record: 7

## About

Aileron Therapeutics, Inc. focuses on advancing therapeutics for cancer and other diseases by developing innovative treatments that utilize a proprietary platform for drug design and delivery.Founded in 2005 and headquartered in Watertown, US, Aileron Therapeutics, Inc. specializes in innovative therapies for cancer treatment. The company has undergone strategic funding rounds to support its growth, with the latest being a Private Placement in January 2021, where they raised USD 35.90 mn. The firm has raised a total of USD 35.90 mn across various funding initiatives since inception. The CEO, Manuel Aivado, leads the company, which has engaged in 13 deals to date.Aileron Therapeutics is dedicated to the development of multi-pathway therapeutics aimed at treating cancer. The company's primary offering is a proprietary platform that enables the design of drugs targeting specific pathways in cancer biology, thereby aiming to improve therapeutic efficacy. Their clientele includes healthcare providers and pharmaceutical partners engaged in oncology.In 2020, Aileron Therapeutics reported a revenue of USD 0 and an EBITDA of -USD 16.16 mn. The company's revenue model emphasizes partnerships and the potential commercialization of its therapeutic products upon successful development and regulatory approval.Aileron Therapeutics plans to leverage its most recent funding round to advance its product pipeline, focusing on launching new therapies targeting cancer pathways. The company aims to expand into European markets by 2023, enhancing its reach and impact. The USD 35.90 mn raised in January 2021 will facilitate research and development efforts, supporting clinical trials and potential market entry.

## Funding rounds

- Series E, Oct 29, 2014, $20M — Novartis Venture Fund, Lilly Ventures, SR One, Apple Tree Partners, AJU IB Investment, Excel Venture Management, Roche Venture Fund
- Series E, Nov 8, 2013, $15M — Novartis Venture Fund, Lilly Ventures, SR One, Apple Tree Partners, Excel Venture Management, Roche Venture Fund
- Series D, Jan 1, 2013, $15M — Novartis Venture Fund, Lilly Ventures, SR One, Apple Tree Partners, Excel Venture Management, Roche Venture Fund
- Series D, May 29, 2009, $28M — Novartis Venture Fund, Lilly Ventures, SR One, Apple Tree Partners, Excel Venture Management, Roche Venture Fund
- Series C, Apr 3, 2008, $0.3M — Novartis Venture Fund, Apple Tree Partners
- Series C, Nov 28, 2007, $10M — Novartis Venture Fund
- Series C, Jun 6, 2007, $7M — Novartis Venture Fund, Apple Tree Partners

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C, Series D, Series E
- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series C, Series D, Series E
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series D, Series E
- SR One (https://capitalatlas.ai/funds/sr-one) — Series D, Series E
- Excel Venture Management (https://capitalatlas.ai/funds/excel-venture-management) — Series D, Series E
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series D, Series E
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series E